KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Retained Earnings (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Retained Earnings data on record, last reported at $7.8 billion in Q1 2025.

  • For Q1 2025, Retained Earnings fell 17.08% year-over-year to $7.8 billion; the TTM value through Mar 2025 reached $7.8 billion, down 17.08%, while the annual FY2025 figure was $7.8 billion, 19.18% down from the prior year.
  • Retained Earnings reached $7.8 billion in Q1 2025 per TAK's latest filing, down from $9.4 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $14.3 billion in Q1 2021 and bottomed at $7.8 billion in Q1 2025.
  • Average Retained Earnings over 5 years is $11.2 billion, with a median of $11.7 billion recorded in 2023.
  • Peak YoY movement for Retained Earnings: rose 13.37% in 2021, then dropped 19.43% in 2024.
  • A 5-year view of Retained Earnings shows it stood at $14.3 billion in 2021, then fell by 10.74% to $12.7 billion in 2022, then fell by 8.5% to $11.7 billion in 2023, then decreased by 19.43% to $9.4 billion in 2024, then decreased by 17.08% to $7.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $7.8 billion in Q1 2025, $9.4 billion in Q1 2024, and $11.7 billion in Q1 2023.